RUBIVet: Rapid Urine based Bacteria Identification for Veterinary Applications

英国皇家兽医学院最近对532例兽医手术进行的一项调查显示，由于新冠肺炎疫情期间实施的社交疏远措施，99%的患者每周营业额明显下降，其中66%的患者报告下降51%或更多。在532个兽医手术中，有451个还报告说，他们现在已转到远程会诊，其中包括新开和重复开处方。近一个世纪以来，两天实验室检测一直是诊断细菌感染的主要手段，对于远程会诊来说，这本身就是次要的。在这个项目中，我们将与兽医市场领导者Anvajo GmbH密切合作，在Anvajo现有的FluidLab R-300设备上提供快速细菌鉴定平台。这将以黄金标准的时间、成本和不便，保持完全实验室分析所预期的结果的相同质量。

According to a recent survey of 532 veterinary surgeries by the Royal College of Veterinary Surgeons, 99% had noticeable reductions in weekly turnover, with 66% reporting reductions of 51% or more, as a result of social distancing measures implemented during the covid-19 pandemic. 451 of the 532 veterinary surgeries also reported that they had now moved to remote consultations which included new and repeat prescribing. 2-day laboratory testing has been the main stay for diagnosis of bacterial infections for nearly a century and is inherently sub-optimal for remote consultations. Our motivation is to challenge this distinct lack of innovation in this market and address the growing frustration amongst modern veterinarian with a simple, all-in-one solution to urine testing in animals.In this project, we will be working closely with veterinary market leaders Anvajo GmBH, to deliver a rapid bacterial identification platform on Anvajo's pre-existing fluidlab R-300 device. This would maintain the same quality of results expected from a full laboratory analysis at a fraction of time, cost and inconvenience of the gold standard.